# Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

> **NCT06582524** · PHASE3 · COMPLETED · sponsor: **Immedica Pharma AB** · enrollment: 3 (actual)

## Conditions studied

- Arginase 1 Deficiency

## Interventions

- **DRUG:** Pegzilarginase

## Key facts

- **NCT ID:** NCT06582524
- **Lead sponsor:** Immedica Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-30
- **Primary completion:** 2025-06-17
- **Final completion:** 2025-06-17
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06582524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06582524, "Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06582524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*